Cambridge Innovation invests up to £1m in Congenica
Cambridge Innovation Capital (CIC) has invested up to £1m in Congenica, a provider of technology for diagnosing rare genetic diseases in children.
The funds will allow Congenica to accelerate the production of its Spienta technology, which the VC stated allows clinicians to speed up the diagnosis of genetic diseases from years to minutes.
CIC stated it was attracted by the business's potential to transform genome analysis services.
The investment is the fifth to be made by the VC's maiden vehicle, which raised £50m in 2013 to invest in high-growth technology companies based in the Cambridge cluster.
In August 2014, the investor made its maiden investments by backing Cambridge Imaging Systems, Origami Energy and Jukedeck. The following month, it led a £4m funding round for Inviata, a spinout of Cancer Research UK.
Company
Headquartered in Cambridge, Congenica is a provider of clinical genome analytics and clinical decision support for medical professionals designed to enable the diagnosis of rare genetic diseases in children.
People
Investment director Dr Robert Tansley led the deal for Cambridge Innovation Capital. Dr Matthew Hurles is co-founder of Congenica.
More on Early-stage
Sidekick spinoffs: Insurtech scale-ups attract PE interest
Investment set to break EUR 1.1bn mark this year as sponsors seek for rising stars
World Fund leads EUR 128m raise for quantum computing group IQM
Series-A2 for Finnish startup focused on combating the climate crisis also backed by the EIB
Gorillas raises circa USD 1bn in Delivery Hero-led Series C
New funding comes just seven months after a Series B, with the company doubling in value
French mega-rounds shoot up in 2021
France has already seen as many rounds of EUR 100m and above than in 2019 and 2020 combined, Unquote Data shows
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater